OS05.6 Final risk model for Temozolomide (TMZ)-Myelotoxicity in patients with Glioblastoma treated on NRG Oncology’s RTOG 0825T. S. Armstrong,M. R. Gilbert,M. Bondy,E. Sulman,Y. Yuan,R. Zhou,E. Vera,M. Wendland,S. Pugh,M. ScheurerNeuro-oncology(2017)引用 1|浏览57暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要